Antihistamines for Postacute Sequelae of SARS-CoV-2 Infection

Melissa D. Pinto, Natalie Lambert, Charles A. Downs, Heather Abrahim, Thomas D. Hughes, Amir M. Rahmani, Candace W. Burton, Rana Chakraborty

Research output: Contribution to journalArticlepeer-review


Postacute sequelae of SARS-CoV2 (PASC) infection is an emerging global health crisis, variably affecting millions worldwide. PASC has no established treatment. We describe 2 cases of PASC in response to opportune administration of over-the-counter antihistamines, with significant improvement in symptoms and ability to perform activities of daily living. Future studies are warranted to understand the potential role of histamine in the pathogenesis of PASC and explore the clinical benefits of antihistamines in the treatment of PASC.

Original languageEnglish (US)
Pages (from-to)335-338
Number of pages4
JournalJournal for Nurse Practitioners
Issue number3
StatePublished - Mar 2022


  • COVID-19
  • SARS-CoV-2 infection (PASC)
  • antihistamine
  • long-COVID
  • long-haul COVID
  • postacute SARS-CoV-2 infection (PASC)
  • treatment

ASJC Scopus subject areas

  • Advanced and Specialized Nursing


Dive into the research topics of 'Antihistamines for Postacute Sequelae of SARS-CoV-2 Infection'. Together they form a unique fingerprint.

Cite this